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Background:Headache is themost commonneurological symptomand a leading cause of years livedwith disabil-
ity.We sought to identify the genetic variants associatedwith a broadly-deﬁned headache phenotype in 223,773
subjects from the UK Biobank cohort.
Methods:We deﬁned headache based on a speciﬁc question answered by the UK Biobank participants. We per-
formed a genome-wide association study of headache as a single entity, using 74,461 cases and 149,312 controls.
Results:We identiﬁed 3343 SNPs which reached the genome-wide signiﬁcance level of P b 5 × 10−8. The SNPs
were located in 28 loci, with the top SNP of rs11172113 in the LRP1 gene having a P value of 4.92 × 10−47. Of
the 28 loci, 14 have previously been associated with migraine. Among 14 new loci, rs77804065 with a P value
of 5.87 × 10−15 in the LINC02210-CRHR1 gene was the top SNP. Signiﬁcant relationships between multiple
brain tissues and genetic associations were identiﬁed through tissue expression analysis. We also identiﬁed sig-
niﬁcant positive genetic correlations between headache and many psychological traits.
Conclusions:Our results suggest that brain function is closely related to broadly-deﬁnedheadache. In addition,we
found that many psychological traits have genetic correlations with headache.
© 2018 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Headache is the most common neurological symptom, with a life
time prevalence of over 90% in the general population in the UK
(Boardman et al., 2003). It represents 4.4% of consultations in primary
care and 30% of outpatient consultations in neurology (Larner, 2006;
Latinovic et al., 2006).
According to the International Headache Society, headache can be
generally divided into two categories: primary headache, if not
associatedwith another disorder; and secondary headache if associated
with an underlyingmedical illness (Headache Classiﬁcation Committee
of the International Headache Society, 2013). Primary headachesmainly
includemigraine, tension-type, and cluster headaches. Secondary head-
aches include any head pain caused by infection, neoplasm, head injury,
somemetabolic disorders, or drugs (Headache Classiﬁcation Committee
of the International Headache Society, 2013).
In a comprehensive review of population-based epidemiological
studies of headache, the global prevalence of recurrent headache in all
ages was found to be 46% for all headaches, including 11% for migraine
and 42% for tension-type headache (Stovner et al., 2007). Tension-type
headache is the most prevalent type of headache, whereas migraine is
the most disabling (Riesco et al., 2007).
Migraine affects around 6million people in England in the age range
16–65 and it is the sixth cause in terms of years of life lost to disability
according to the Global Burden of Diseases 2013 (Global Burden of
Disease Study 2013 Collaborators, 2015). Migraine costs the National
Health Service almost £2 billion per year (Steiner et al., 2003). It pre-
sents with recurrent headache attacks and/or hypersensitivity to light
and sound. Around one third of migraineurs experience an aura,
which are transient neurological symptomsmostly involving the visual
system (Silberstein, 2004).
Family studies and twin studies have suggested that both migraine
and tension-type headache are heritable traits with a heritability over
40% (Russell et al., 2007; Schürks, 2012). Recently, genome-wide associ-
ation studies (GWAS) have identiﬁedmany genetic loci associated with
migraine (Anttila et al., 2010; Anttila et al., 2013; Chasman et al., 2011;
Freilinger et al., 2012; Ligthart et al., 2011). A GWAS meta-analysis of
375,000 patients involving 22 centers has identiﬁed 38 genetic suscep-
tibility loci for migraine with the LRP1 region in chromosome 12 being
the most strongly associated (Gormley et al., 2016a). Along with other
GWAS on migraine, the total number of loci identiﬁed to be associated
with migraine is currently 47 (Gormley et al., 2016b). No GWAS have
been performed for tension-type headache so far.
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There are several phenotypic associations between headache and
metabolic, psychological, and other factors such as obesity (Scher et
al., 2003;Waldie and Poulton, 2002). Genome-wide association studies
provide a potential route to discover genetic correlations with other
complex traits and diseases that in turnmay provide clues to shared ge-
netic architectures and etiologies (Bulik-Sullivan et al., 2015a).
To identify the genetic variants associated with headache, we con-
ducted this GWAS using the UK Biobank cohort which has never been
contributed to genetic studies of headache including migraine. We
used a broadly-deﬁned headache phenotype, the one available in the
UK Biobank dataset. Secondly, we sought to test for shared genetic
associations with other complex traits and diseases using linkage-
disequilibrium score regression (Bulik-Sullivan et al., 2015b).
2. Materials and Methods
2.1. Participants and Genetic Information of Participants
The UK Biobank is a health research resource that aims to improve
the prevention, diagnosis and treatment of a wide range of illnesses.
The UK Biobank cohort recruited over 500,000 people aged between
40 and 69 years in 2006–2010 across the UK. Participants completed a
detailed clinical, demographic, and lifestyle questionnaire, underwent
clinical measures, provided biological samples (blood, urine and saliva)
for future analysis, and agreed to have their health records accessed. The
informed consent of all participants has been obtained. Details of theUK
Biobank resource can be found at www.ukbiobank.ac.uk. UK Biobank
received ethical approval from the National Health Service National Re-
search Ethics Service (reference 11/NW/0382). The current analyses
were conducted under approved UK Biobank data application number
4844.
The detailed methods of DNA extraction and quality control can be
found at http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/
DNA-Extraction-at-UK-Biobank-October-2014.pdf. Participants' DNA
was genotyped by bespoke Affymetrix UK Biobank chips. Standard QC
steps were performed by the Wellcome Trust Centre for Human
Genetics at Oxford University. The detailed QC steps can be found at
http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=155580.
In July 2017, the genetic information (including directly genotyped
genotypes and imputed genotypes) from501,708 samples was released
to UK Biobank project research collaborators. The detailed QC steps of
imputation are described by Bycroft et al. (Bycroft et al., 2017).
2.2. Phenotypic Information on Pain
The UK Biobank participants were offered a pain-related question-
naire, which included the question: ‘in the last month have you experi-
enced any of the following that interfered with your usual activities?’.
The options were: 1. Headache; 2. Facial pain; 3. Neck or shoulder
pain; 4. Back pain; 5. Stomach or abdominal pain; 6. Hip pain; 7. Knee
pain; 8. Pain all over the body; 9. None of the above; 10. Prefer not to
say. Participants could select more than one option. (UK Biobank Ques-
tionnaire ﬁeld ID: 6159).
The headache cases in this study were those who selected the
‘Headache’ option for the above question, regardless of whether they
had selected other options.
The controls in this study were those who selected the ‘None of the
above’ option.
2.3. Statistical Analysis
In this study, we used BGENIE (https://jmarchini.org/bgenie/) to be
themain GWAS software and removed single nucleotide polymorphism
(SNPs) with INFO scores b 0.1, with minor allele frequency b 0.5%, or
those that failed Hardy-Weinberg tests P b 10−6. SNPs on the X and Y
chromosomes and mitochondrial SNPs as well as imputed SNPs that
were not in the Haplotype Reference Consortium panel were excluded
from analyses. Standard Frequentist association tests using BGENIE
was used to perform association studies adjusting for age, sex, body
mass index (BMI), 9 population principal components, genotyping
arrays, and assessment centers. Gender difference between cases and
controls was compared using chi-square testing. Age and BMI were
compared using independent t testing in IBM SPSS 22 (IBMCorporation,
New York). SNP associations were considered signiﬁcant if they had a
P value b 5 × 10−8. GCTA was used to calculate SNP-based or narrow-
sense heritability (Yang et al., 2011) using a genomic relationship ma-
trix calculated from genotyped autosomal SNPs.
SNP functional annotations were applied by the FUMA web
application and a Manhattan plot was generated by R (Watanabe et
al., 2017). R was also used to generate the corresponding Q-Q plot, a
tool to evaluate differences between cases and controls caused by po-
tential confounders.
The gene analysis and gene-set analysis were performed with
MAGMA v1.6, which was integrated in FUMA (de Leeuw et al., 2015).
Both analyses were based on GWAS summary statistics. In gene analy-
sis, summary statistics of SNPs are aggregated to the level of whole
genes, testing the joint association of all SNPs in the gene with the phe-
notype. In gene-set analysis, individual genes are aggregated to groups
of genes sharing certain biological, functional or other characteristics.
Thiswill provide insight into the involvement of speciﬁc biological path-
ways or cellular functions in the genetic etiology of a phenotype. Tissue
expression analysis was obtained from GTEx (https://www.gtexportal.
org/home/) which was also integrated in FUMA. The purpose of using
FUMA web application was to provide extra information to visualize
and interpret GWAS results.
In order to identify genetic correlations betweenheadache and other
complex traits,we used linkage disequilibriumscore regression through
LD Hub v1.4.1 (available at http://ldsc.broadinstitute.org/ldhub/)
(Zheng et al., 2017). This web-tool uses individual SNP allele effect
sizes and the average linkage disequilibrium in a region to estimate
the bivariate genetic correlations of headache with 234 traits. Those
with P values of 2.1× 10−4 (0.05/234) or less should be regarded as sur-
viving Bonferroni adjustment for multiple testing.
3. Results
3.1. GWAS Results
During the initial assessment visit (2006–2010), at which partici-
pants were recruited and consent was given by 501,708 UK Biobank
participants, the speciﬁc pain question (see the Materials and
Methods section for details) received 775,252 responses to all options.
Among these responses, the number of participants who selected the
‘Headache’ option was 102,994 (cases), and the number of participants
who selected the ‘None of the above’ option was 197,149 (controls).
We further removed those whose ancestry was not white British
(n= 22,694) based on principal component analysis, those who were
related to one or more others in the cohort (a cut-off value of 0.025 in
the generation of the genetic relationship matrix) (n = 52,166), those
who were also participants in a Psychiatric Genomics Consortium
Major Depressive Disorder cohort (n = 597), and those who failed
quality-control (QC) (n = 913). Thus we ﬁnally identiﬁed 74,461
cases (27,350 males and 47,111 females) and 149,312 controls
(71,480 males and 77,832 females) for the GWAS association analysis.
After quality control, there were 9,304,965 SNPs for the GWAS analysis.
The clinical characteristics of these cases and controls are summa-
rized in Table 1. There were statistical differences (P b 0.001) in age,
sex and BMI between cases and controls.
We identiﬁed 3343 SNPs which reached GWAS signiﬁcance of P b 5
× 10−8 (Fig. 1, Supplementary Table 1). These SNPs represented 28 in-
dependent loci including 14 newly-identiﬁed loci (Table 2).
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The ﬁrst cluster was in the LDL receptor related protein 1 (LRP1) gene
in the chromosome 12 area with a lowest P value of 4.92 × 10−47 for
rs11172113 (C allele, odds ratio (OR): 0.98). The second cluster was in
the four and a half LIM domains 5 (FHL5) gene in chromosome 6 with a
lowest P value of 2.58 × 10−31 for rs9486715 (C allele, OR: 1.02).
Among the 28 loci, 14 of them were newly identiﬁed. Rs77804065 in
the LINC02210-CRHR1 readthrough (LINC02210-CRHR1) gene with a
P value of 5.87 × 10−15 (T allele, OR: 1.01) was the most strongly
associated among the newly-identiﬁed loci. The Q-Q plot of the GWAS
is shown in the Supplementary Fig. 1. The SNP-based heritability of
broadly-deﬁned headache was 0.211 (standard error = 0.015).
3.2. Gene Analysis, Gene-Set Analysis and Tissue Expression Analysis by
FUMA
In the gene analysis byMAGMA integrated in FUMA, all the SNPs are
mapped to 19,436 protein coding genes if the SNPs are located within
genes. The default SNP-wise (mean) model for the gene analysis was
applied. The signal transducer and activator of transcription 6 (STAT6)
gene reached the lowest P value of 1.1 × 10−46, followed by UFM1 spe-
ciﬁc ligase 1 (UFL1) (P= 2.53 × 10−26), FHL5 (P= 8.64 × 10−25) and
LRP1 (P = 3.85 × 10−23). All genes (N = 160) with a P b 3 × 10−6
(0.05/19436) are included in the Supplementary Table 2.
In the gene set analysis by MAGMA integrated in FUMA, a total of
10,894 gene sets were tested and a default competitive test model
was applied. Gene sets of positive regulation of gene expression, posi-
tive regulation of transcription from RNA polymerase ii promoter,
neurogenesis, and excitatory synapse reached a P value b 0.0001, but
not statistical signiﬁcant of P b 5 × 10−6 (0.05/10,894). The top 10
gene sets from the analysis were included in the Supplementary Table 3.
In the tissue expression analysis by GTEx integrated in the FUMA, av-
erage gene-expression per tissue typewas used as gene covariate to test
positive relationship between gene expression in a speciﬁc tissue type
and genetic associations. Two types of tissue analysis were performed.
One used 30 general tissue types and the other used 53 speciﬁc tissue
types. In the expression analysis of 30 general tissue types, the tissue
in the brain showed the most signiﬁcant P value (P = 4.12 × 10−6),
followed by the tissue from blood vessel (P= 0.014) (Supplementary
Table 4). In the 53 speciﬁc tissue types, tissues from the brain cortex
reached a lowest P value of 1.44 × 10−5 and most of the brain speciﬁc
tissues also reached a signiﬁcant P value of 0.001 (0.05/53). See Fig. 2
and Supplementary Table 5.
3.3. Genetic Correlation Analysis by LD Hub
Through the genetic correlation analysis, we identiﬁed multiple sig-
niﬁcant positive correlations for headache (Supplementary Table 6).
The signiﬁcant genetic correlations (rg) surviving multiple testing cor-
rection (P b 0.05/234) were: neuroticism (rg = 0.50, P = 2.24
× 10−72), depressive symptoms (rg = 0.52, P = 1.60 × 10−46), years
of education (rg =−0.28, P= 5.25 × 10−37), maternal age at ﬁrst de-
livery (rg = −0.32, P = 3.97 × 10−29), subjective wellbeing (rg =
−0.37, P = 9.51 × 10−19), insomnia (rg = 0.42, P = 2.54 × 10−18),
and major depressive disorder (rg = 0.39, P= 1.57 × 10−11).
4. Discussion
We have performed a GWAS on broadly-deﬁned headache as a
single entity using the UK Biobank resource and found that variants
in 28 loci were associated with having experienced headache within
the last month to the extent that it interfered with usual activities.
Evidence from tissue expression analysis showed that brain function
is closely related to this broadly-deﬁned headache. In addition, we
found that headache was genetically correlated with a number of
psychological factors, including those linked to a higher tendency
toward experiencing negative emotional states, and shorter duration
of education.
In this study, we deﬁned headache cases and controls based on the
responses by UK Biobank participants to a speciﬁc pain question. This
question focused on headache occurrence, sufﬁcient to cause interfer-
ence with activities, during the previous month. We can therefore
only treat headache as a global condition to perform GWAS. We can
Table 1
Clinical characteristics of headache cases (74,461) and controls (149,312).
Covariates Cases Controls Pb
Sex (male:female) 27,350: 47,111 71,480: 77,832 b0.001
Age (years) 54.38 (7.95) 56.93 (7.97) b0.001
BMIa (kg/m2) 27.50 (5.05) 26.66 (4.30) b0.001
Continuous covariates were presented as mean (standard deviation).
a BMI: body mass index.
b A chi-square test was used to test the difference of gender frequency between cases
and controls and an independent t-test was used for other covariates.
Fig. 1. The Manhattan plot of the GWAS on headache using the UK Biobank cohort.
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hypothesize, based on the reported population prevalence of each sub-
type (Stovner et al., 2007; Riesco et al., 2007), that tension-type head-
ache will be the most common diagnosis among cases, followed by
migraine, and that many will have experienced more than one type of
headache. Whether the SNPs identiﬁed are associated with one or
more of these diagnoses speciﬁcally, or with headache globally remains
unclear until further research is conducted. It is important to note that
half of the 28 loci were previously reported loci for migraine (Table 2).
The UK Biobank genetic resource is especially useful as a screening
tool to test whether heterogeneous phenotypes such as headache
have genetic components at all, as the UK Biobank has collected many
heterogeneous phenotypes which need further genetic investigation.
Table 2
Summary of the 28 loci associated with broadly-deﬁned headache.
Locus rank Gene Chromosome Lead SNP P Effective allele MAFa Beta SEb New loci?
1 LRP1-STAT6-SDR9C7 12 rs11172113 4.92 × 10−47 C 0.38 −0.0202 0.0014
2 FHL5-UFL1 6 rs9486715 2.58 × 10−31 C 0.35 0.0171 0.0015
3 TRPM8-HJURP 2 rs2362290 6.25 × 10–16 A 0.17 −0.0141 0.0017
4 PHACTR1 6 rs9349379 3.59 × 10−15 G 0.40 −0.0110 0.0014
5 LINC02210-CRHR1-MAPT 17 rs77804065 5.87 × 10−15 T 0.25 0.0130 0.0017 New locus
6 Intergenic 1 rs12740679 3.66 × 10−12 G 0.26 0.0110 0.0016 New locus
7 Intergenic 10 rs78438709 8.57 × 10−12 G 0.07 −0.0186 0.0027
8 MEF2D 1 rs1050316 1.54 × 10−11 T 0.33 −0.0098 0.0015
9 ASTN2 9 rs17220352 9.42 × 10−11 G 0.25 0.0104 0.0016
10 Intergenic 3 rs34097149 1.33 × 10−10 C 0.03 −0.0297 0.0046
11 Intergenic 6 rs9490318 1.72 × 10−10 T 0.14 0.0124 0.0019
12 Intergenic 1 rs12134493 1.93 × 10−10 A 0.11 0.0136 0.0021
13 Intergenic 18 rs4941139 2.22 × 10−10 C 0.32 0.0093 0.0015 New locus
14 CAMK1D 10 rs2895526 4.61 × 10−10 A 0.48 −0.0086 0.0014 New locus
15 PRDM16 1 rs56304645 5.74 × 10−10 T 0.26 0.0102 0.0016
16 NUFIP2 17 rs8614 4.25 × 10−9 A 0.19 0.0105 0.0018 New locus
17 Intergenic 12 rs10774231 4.55 × 10−9 C 0.42 −0.0082 0.0014
18 MRVI1 11 rs4909945 5.13 × 10−9 C 0.30 0.0087 0.0015
19 BTN2A2 6 rs2072806 5.30 × 10−9 G 0.12 −0.0121 0.0021 New locus
20 Intergenic 1 rs7555006 5.87 × 10−9 G 0.44 0.0081 0.0014 New locus
21 MYO1H 12 rs6606710 8.44 × 10−9 C 0.42 0.0084 0.0015 New locus
22 IFT81 12 rs7300001 8.86 × 10−9 G 0.10 −0.0144 0.0025 New locus
23 NOL4L 20 rs1555132 1.16 × 10−8 A 0.34 0.0083 0.0015 New locus
24 CFDP1 16 rs1011121 1.46 × 10−8 G 0.43 −0.0080 0.0014
25 PTBP2 1 rs3748784 1.75 × 10−8 G 0.47 −0.0078 0.0014 New locus
26 FXN 9 rs4596713 2.30 × 10−8 T 0.41 −0.0078 0.0014 New locus
27 ATG13 11 rs56349329 3.69 × 10−8 A 0.16 −0.0104 0.0019 New locus
28 MACF1 1 rs2036465 4.01 × 10−8 C 0.20 −0.0093 0.0017 New locus
a MAF: minor allele frequency.
b SE: standard error.
Fig. 2. The tissue expression results on 53 speciﬁc tissue types by GTEx in FUMA.
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An example of such a GWAS approach was adopted by Deary et al. on
self-reported tiredness (a heterogeneous phenotype) using the UK
Biobank cohort (Deary et al., 2016). GWAS like this will help with ge-
netic stratiﬁcation analysis for heterogeneous phenotypes. This genetic
discovery phase could be part of the partitioning or classiﬁcation of
broadly-reported or broadly-deﬁned headache, improving our under-
standing of its etiology, diagnosis, prognosis and the development of
treatments.
The ﬁndings of this research will facilitate the next essential phases
of research into the genetics and causes of headache. They will enable
investigators to conduct adequate power calculations for future studies
and will provide candidate loci to examine in replication studies. Even
with our very heterogeneous group of cases, including many different
headache subtypes,wewere still able to identify numerousGWAS asso-
ciations. Therefore, it can be expected that in a GWAS of a more inten-
sively-phenotyped headache cohort or a subtype of headache such as
tension-type headache for which no GWAS has yet been performed,
genetic contributions could be more distinctive and easier to identify
than in this study (for example, GWAS hits can be identiﬁed using
fewer samples). Since our results are of GWAS signiﬁcance, the genes
(such as LRP1 and FHL5) identiﬁed for migraine by other GWAS are
also promising candidate genes for tension-type headache. Themajority
of the patients with migraine (over 90%) also suffer from tension-type
headache (Lyngberg et al., 2005), and it is possible that migraine and
tension-type headache might share common genetic components.
In this GWAS, we have identiﬁed 28 loci for headache. One was in
the LRP1 gene with a lowest P value of 4.92 × 10−47 for rs11172113.
The LRP1 gene encodes a precursor protein that is processed by furin
in the trans-Golgi complex, generating a 515 kDa alpha-chain and an
85 kDa beta-chain associated non-covalently (Lillis et al., 2008). This
protein is involved inmultiple cellular processes, including intracellular
signaling, lipid homeostasis, and clearance of apoptotic cells (Etique et
al., 2013). The LRP1 gene has also been reported to be associated with
Alzheimer's disease, cardiovascular disease, and tumors (Kanekiyo and
Bu, 2014; Llorente-Cortés and Badimon, 2005; Song et al., 2009).
Chasman et al. ﬁrst identiﬁed the association between the LRP1 gene
and migraine in a Caucasian population (Chasman et al., 2011). The as-
sociation was then replicated by Freilinger et al. in migraine without
aura in German and Dutch patients (Freilinger et al., 2012). The locus
was further replicated in Indian but not in Chinese populations (Fan et
al., 2014; Ghosh et al., 2013). It is worth noting that many nearby
supporting SNPs for the LRP1 region were located in the nearby gene
of STAT6 (which was also strongly associated with headache).
The second SNP cluster was in the FHL5 gene area with a lowest
P value of 2.58 × 10−31 for rs9486715. The protein encoded by this
gene is expressed with activator of cAMP-responsive element modula-
tor (CREM) (Fimia et al., 1999). It is associated with CREM and confers
a powerful transcriptional activation function (Fimia et al., 1999). The
locus was ﬁrst reported by Anttila et al. to be associated with migraine
(Anttila et al., 2013). Although replication failed in a Chinese population,
the locus was replicated by Gormley et al. in a large meta-analysis on
migraine (Gormley et al., 2016a; Lin et al., 2015). Both the LRP1 and
FHL5 genes are also candidate genes for cervical artery dissection sug-
gesting vascular involvement in headache (Gormley et al., 2016b). Just
as the LRP1 region extends to the STAT6 gene, the FHL5 cluster extends
to the UFL1 gene.
The strongest association among the 14 newly proposed loci is
located in the LINC02210-CRHR1 gene. The corticotropin releasing
hormone receptor 1 (CRHR1) gene has been reported to be associated
with stress, panic disorder, neuroticism (Henckens et al., 2016; Weber
et al., 2016; DeYoung et al., 2011). This is matchedwith our genetic cor-
relation results by LD hub suggesting headache and psychological traits
share genetic architectures (see Discussion below). The locus extends to
the microtubule associated protein tau (MAPT) gene region. Other new
identiﬁed loci included: calcium/calmodulin dependent protein kinase
ID (CAMK1D), NUFIP2, FMR1 interacting protein 2 (NUFIP2), butyrophilin
subfamily 2 member A2 (BTN2A2), myosin IH (MYO1H), intraﬂagellar
transport 81 (IFT81), nucleolar protein 4 like (NOL4L), polypyrimidine
tract binding protein 2 (PTBP2), frataxin (FXN), autophagy related 13
(ATG13), microtubule-actin crosslinking factor 1 (MACF1) and some
intergenic regions. It is interesting to notice that GWAS have identiﬁed
that CAMK1D andMACF1 are involved in vascular disorders (hyperten-
sion and peripheral artery disease) (Frau et al., 2014; Ward-Caviness
et al., 2016), again supporting a vascular contribution to headache.
It is also interesting to note that the STAT6 gene was themost signif-
icant in the gene analysis with headache and not the LRP1 gene where
the top SNP resides. These two genes are next to each other in the ge-
nome and have previously been associated with disorders related to
the immune system such as food allergen sensitization and Sjogren's
Disease (Hancock et al., 2012; Johar et al., 2015). It is reported that
IL4/STAT6 signaling activates neural stem cell proliferation and
neurogenesis in zebraﬁsh brain, which indicates the importance of the
gene in neuron function (Bhattarai et al., 2016). The gene sets analysis
revealed that genes involved in the neurogenesis are associated with
headache which is consistent with the tissue expression analysis.
Both tissue expression analysis on 30 general tissue types and 53
speciﬁc tissue types showed signiﬁcant associations between brain tis-
sues and headache, but not vascular tissues. This conclusion is different
from the predominant theory of vascular etiology formigraine since our
results suggest that brain function is closely related to broadly-deﬁned
headache. Combining all results from GWAS and FUMA together, it is
clear that both neuronal and vascular factors are involved in the head-
ache mechanism.
Consistent with previous studies from our group, we found strong
evidence to support a shared genetic etiology of painwith psychological
traits, indicating a vulnerability to depression and other negative mood
states (McIntosh et al., 2016; van Hecke et al., 2017). In addition, we
found a negative correlation with factors associated with a longer
duration of education. Previous results have suggested that headache
sufferers were more likely to have psychiatric disorders than healthy
people (Mitsikostas and Thomas, 1999). In addition, a shared genetic
link between migraine and depression has been identiﬁed (Stam et al.,
2010). Further studies are needed to demonstrate the nature of these
correlations and whether any directional ‘causal’ inferences can be
drawn.
The SNP-based heritability for broadly-deﬁned headache was 0.211
in our study, which is less than previously reported broad-sense herita-
bility ofmigraine and tension-type headacheof 40% (Russell et al., 2007;
Schürks, 2012). This can be explained that the SNP-based heritability
does not take gene-gene interactions and gene-environment interac-
tions into account.
The Q-Q plot suggested that there are residual confounding factors
between headache cases and controls which have not been adjusted
for. Those could be factors associated with psychiatric and vascular
disorders. We also noted there is a 90 degree upswing (around the
P= 10−14 level). This is due to the fact that we have a cluster of 1800
signiﬁcant SNPs at this level (mainly located at the LINC02210-CRHR1-
MAPT loci), which is over half of the total number of signiﬁcant SNPs.
Using the CaTS power calculator, we had 80% power to identify SNP
associationswith a signiﬁcance level of 5 × 10−8, based on 74,461 cases
and 149,312 controls, assuming an additive model, a minor disease al-
lele frequency of 0.15, a genotypic relative risk of 1.05, and a prevalence
of headache in the general population of 0.2 (a conservative assump-
tion) (Skol et al., 2006).
The main limitation of our study is that the phenotyping was based
on a speciﬁc pain-related question used by the UK Biobank cohort and
was therefore broadly-deﬁned. The speciﬁc pain question does not ask
for any information about the headache severity, nor does it provide
subgrouping opportunities such as differentiating migraine from ten-
sion-type headache or secondary headache types. In the future, when
there is a new round of pain questionnaires to participants in the UK
Biobank, more detailed and focused phenotyping would be generated.
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We have identiﬁed 28 loci for broadly-deﬁned headache as a single
entity in a GWAS using the UK Biobank resource, including 14 loci that
have previously been associated with migraine, and 14 loci that have
not previously been associated with headache. This is the largest
GWAS on headache in a single population so far. We also identiﬁed
evidence that brain function is closely related to broadly-deﬁned
headache. In addition, we found several signiﬁcant correlations with a
number of psychological factors, suggesting that the genetic etiology
of headache may also be related to these traits. These ﬁndings will not
only contribute to the understanding of the causes of headache
(and its subtypes) and its relationships with psychological disorders, it
might also bring potential genetic target for drug treatment for patients
with headache and psychological disorders.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2018.01.023.
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